OTOTOXIC EFFECTS OF ANTINEOPLASTIC DRUGS: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i8.1784Keywords:
Antineoplastic drugs, cisplatin, exposure, hearing, ototoxicityAbstract
Introduction: When scientific evidence is reviewed, platinum-based chemotherapeutics are essential in cancer treatment at various levels and are the most referenced ototoxic drugs.
Aim: This study aims to give scientific data based on a PRISMA systematic literature review to standardize information on the ototoxic effects of antineoplastic medicines.
Methods: A combination based on the Medical Subject Heading Terms (MeSH) was utilized to choose studies. The databases Medline (Pubmed), LILACS, SciELO, SCOPUS, WEB OF SCIENCE, and BIREME were used without regard to language, period, or region. The quality of the papers was evaluated, and articles with a minimum score of 6 on the modified literature scale were included. The selected studies had descriptive, cohort, and cross-sectional designs connected to the research purpose.
Results: The results of this systematic review included three papers. The ototoxicity caused by cisplatin alone ranged from 45% to 83.3%, while that caused by carboplatin usage ranged from 16.6% to 75%. The cumulative dosages of these antineoplastic drugs, both alone and in combination, varied significantly. After therapy, there were noticeable changes in hearing, particularly at high frequencies.
Conclusion: Auditory alterations were observed following the administration of platinum-based antineoplastic medicines; nevertheless, there was significant variation in the frequency of ototoxicity and the cumulative dose of the drugs administered.
References
De Oliveira Santos M. Estimativa/2020 – Incidência de Câncer no Brasil. Rev Bras Cancerol. 2020;66(1).
Dar M, Sharma K. Burden of cancer in India: GLOBOCAN 2018 Estimates Incidence, Mortality, prevalence and future projections of cancer in India". J Emerg Technol Innov Res. 2019;6(6).
Hur MW, Hahn SM, Moon IS, Lim JY, Lee SM, Lyu CJ, et al. Adverse Factors and the Role of Cisplatin and Vinca Alkaloids for Hearing Impairment in Childhood Cancer Patients and Survivors. Clin Pediatr Hematol. 2017;24(2).
Chaibakhsh S, Zayeri F, Baghestani AR, Bakhshandeh M, Aghamiri SMR, Safari AH. The effect of radiation therapy on hearing loss in patients with head and neck cancer. Int J Cancer Manag. 2018;11(4).
Brooks B, Knight K. Ototoxicity monitoring in children treated with platinum chemotherapy. Vol. 57, International Journal of Audiology. 2018.
Pearson SE, Taylor J, Hoare DJ, Patel P, Baguley DM. Exploring the experiences of cancer patients with chemotherapy-induced ototoxicity: Qualitative study using online health care forums. JMIR Cancer. 2019;5(1).
Freyer DR, Brock PR, Chang KW, Dupuis LL, Epelman S, Knight K, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Vol. 4, The Lancet Child and Adolescent Health. 2020.
Landier W. Ototoxicity and cancer therapy. Vol. 122, Cancer. 2016.
Ding D, Allman BL, Salvi R. Review: Ototoxic Characteristics of Platinum Antitumor Drugs. Vol. 295, Anatomical Record. 2012.
Nitz A, Kontopantelis E, Bielack S, Koscielniak E, Klingebiel T, Langer T, et al. Prospective evaluation of cisplatinand carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett. 2012;5(1).
de Oliveira PF, Oliveira CS, Andrade JS, do Carmo Santos TF, de Oliveira-Barreto AC. Cancer treatment in determination of hearing loss. Braz J Otorhinolaryngol. 2016;82(1).
Oh SY, Wasif N, Garcon MC, Rodriguez G, Saif MW. Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. Vol. 14, Journal of the Pancreas. 2013.
Liberman PHP, Goffi-Gomez MVS, Schultz C, Novaes PE, Lopes LF. Audiological profile of patients treated for childhood cancer. Braz J Otorhinolaryngol. 2016;82(6).
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Rev Esp Nutr Humana y Diet. 2016;20(2).
Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Grenner J, Magnusson M, et al. Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol. 2010;49(10).
Clemens E, de Vries AC, Pluijm SF, am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. Eur J Cancer. 2016;69.
Clemens E, de Vries ACH, am Zehnhoff-Dinnesen A, Tissing WJE, Loonen JJ, Pluijm SFM, et al. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors. Pediatr Hematol Oncol. 2017;34(2).
Clemens E, Meijer AJM, Broer L, Langer T, Van Der Kooi ALLF, Uitterlinden AG, et al. Genetic determinants of ototoxicity during and after childhood cancer treatment: Protocol for the pancarelife study. JMIR Res Protoc. 2019;8(3).
Coradini PP, Cigana L, Selistre SGA, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29(6).
Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23(34).
Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012;30(10).
Soliman SE, D’Silva CN, Dimaras H, Dzneladze I, Chan H, Gallie BL. Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience. Pediatr Blood Cancer. 2018;65(5).
Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer. 2004;40(16).
Lanvers-Kaminsky C, Zehnhoff-Dinnesen A am, Parfitt R, Ciarimboli G. Drug-induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies. Vol. 101, Clinical Pharmacology and Therapeutics. 2017.
Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012;59(1).
Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, Bagby GC. High-Frequency Monitoring for Early Detection of Cisplatin Ototoxicity. Arch Otolaryngol Neck Surg. 1993;119(6).
Sakat MS, Kilic K, Akdemir FNE, Yildirim S, Eser G, Kiziltunc A. The effectiveness of eugenol against cisplatininduced ototoxicity. Braz J Otorhinolaryngol. 2019;85(6).
Sherief LM, Rifky E, Attia M, Ahmed R, Kamal NM, Oshi MAM, et al. Platinum-induced ototoxicity in pediatric cancer survivors: GSTP1 c.313A>G variant association. Med (United States). 2022;101(45).
Lui G, Bouazza N, Denoyelle F, Moine M, Brugières L, Chastagner P, et al. Association between genetic polymorphisms and platinuminduced ototoxicity in children. Oncotarget. 2018;9(56).
Fetoni AR, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G, et al. Audiological monitoring in children treated with platinum chemotherapy. Audiol Neurotol. 2016;21(4).
Phillips OR, Baguley DM, Pearson SE, Akeroyd MA. The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a literature review. Vol. 17, Journal of Cancer Survivorship. 2023.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
